Clinical Trial Update: Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating how steady-state BIA 9-1067 affects the pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide in Parkinson disease. The stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• BIA 9-1067
• Levodopa/Benserazide (levodopa + benserazide)
• Levodopa/Carbidopa (levodopa/carbidopa)

Snippet

Sponsor: Bial - Portela C S.A. | Conditions: Parkinson Disease | Phase 1 | Status: COMPLETED | Results posted: 2015-11-16